As public unease grows over the integrity of the nation’s blood supply, Rhode Island lawmakers have introduced House Bill 7815 to protect patients’ and physicians’ rights to consider autologous or directed blood donations. Introduced on February 26, 2026, by Representatives Charlene Lima and Marie Hopkins, the measure amends Title 23 of the Rhode Island General Laws by adding Chapter 4.15, “Autologous or Direct Blood Donations.”

The bill defines autologous donation as a patient donating their own blood for personal future use and directed donation as blood donated specifically for another identified recipient. It requires hospitals and licensed healthcare facilities that already perform blood donations to permit provider-ordered autologous or directed donations prior to a scheduled procedure. Blood banks must honor a healthcare provider’s prescription unless the donor is in ill health, has a heart condition making donation inadvisable, is underweight, or faces any other medical contraindication. Facilities may charge only their standard fees for facilitation and storage. The Department of Health is tasked with issuing necessary implementing regulations. The act would take effect immediately upon passage.

Current Rhode Island law does not prohibit autologous (self-donated) or directed blood donations. These options have long been legally permitted under federal FDA regulations and have historically been available in the state, including for some patients with anemia who could pre-donate their own blood under physician supervision and with supportive treatments like erythropoietin when appropriate. However, while not banned, they are not currently guaranteed or uniformly offered by all hospitals and blood banks; availability depends on individual facility policies, logistical capacity, and physician orders. HB 7815 seeks to change this by affirmatively requiring facilities that perform blood donations to permit and facilitate medically appropriate autologous or directed donations ordered by a healthcare provider, while still respecting existing FDA safety standards and medical contraindications such as severe anemia, heart conditions, or low body weight. In short, the practices are allowed today but not mandated—HB 7815 would protect and standardize patient access without creating new regulatory burdens.

Supporters frame the legislation as a narrow, patient-centered safeguard for informed medical decision-making. Many citizens have voiced deep concerns that blood from donors who received COVID-19 mRNA vaccines may contain lingering spike proteins or related components capable of triggering adverse effects in recipients. Although major health organizations and recent studies maintain that vaccine components do not persist in the bloodstream long enough to pose transfusion risks, these worries persist among patients facing surgery, trauma care, or chronic conditions requiring transfusions. Some individuals cite personal health histories, religious beliefs, or precautionary principles, preferring blood free from any potential vaccine-derived material. In this context, autologous donations (using one’s own pre-collected blood) or directed donations from trusted, unvaccinated friends or family offer a perceived layer of control and peace of mind.

A Myth vs. Fact sheet issued by proponents directly addresses common objections. It emphasizes that all blood—whether from the general supply, directed donors, or autologous sources—undergoes identical FDA-mandated testing and screening; no reduced safety standards apply. The bill does not compel hospitals to accept or use directed blood, nor does it interfere with physician judgment or hospital operations. Decisions remain squarely between doctor and patient. Directed donations are described as rare and case-specific, posing no threat to the volunteer blood supply. Existing federal regulations already govern these practices, so HB 7815 creates no new bureaucratic burdens. Finally, the legislation mandates physician involvement, ensuring requests are medically appropriate rather than driven by non-clinical motives.

Rhode Island joins a nationwide trend. Similar protections passed successfully in Idaho in 2026, with active bills advancing in 17 other states. The momentum reflects a broader push to preserve medical autonomy without compromising established safety protocols.

Critics worry the measure could stoke unfounded fears or strain limited resources, yet the text and supporting materials make clear that HB 7815 changes nothing about core FDA standards or the primacy of community blood drives. It simply ensures that, when clinically suitable, patients and doctors can openly discuss every available option—including self-donated or specifically directed blood—without fear of institutional barriers.
In an era when trust in medical systems has been tested, HB 7815 stands as a modest but meaningful affirmation of individual rights. By codifying the ability to explore autologous and directed donations, Rhode Island legislators aim to balance collective safety with personal reassurance, letting patients and physicians decide together what blood is best for each unique case. The bill now awaits committee review in the House Health & Human Services Committee, where debate is expected to center on patient autonomy versus operational practicality.